Collaboration Focused on Chloride Channel Blocker
By Biotechdaily staff writers
Posted on 25 Aug 2004
A collaboration has been announced whereby TopoTarget A/S (Copenhagen, Denmark) will help NeuroSearch A/S (Ballerup, Denmark) develop a compound called Endovion (NS3728) for the treatment of cancer.Posted on 25 Aug 2004
Endovion blocks a certain subtype of chloride ion channel important for cell division, cell migration, and the formation of new blood vessels. The compound has shown efficacy in preclinical cancer models and has completed phase I clinical trials in 92 subjects. TopoTarget aims to commence additional preclinical assessment in order to design the phase II clinical studies. Under the terms of the agreement, TopoTarget will fund future preclinical and clinical development, and the two companies will share any future revenues from the product.
"We are delighted to be entering this collaboration,” said Dr. Jorgen Buus Lassen, president and CEO of NeuroSearch. "TopoTarget has significant expertise in oncology and will continue to explore the full potential of Endovion with various cancer types and provide the optimal cancer development experience.”
Related Links:
TopoTarget
NeuroSearch
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
New
Gold Member
STI Test
Vivalytic MG, MH, UP/UU
New
Benchtop Thermomixer
Biometra TS1 ThermoShaker
New
Chromogenic Culture System
InTray™ COLOREX™ ECC
